Antoon Boussu is Global Pricing Lead at Novo Nordisk in Copenhagen, where he leads pricing strategy for early- to late-stage assets across cardiometabolic and liver diseases. He also supports business development through pricing and market access due diligence. Before joining the global pricing team in 2024, he held market access roles at Novo Nordisk BeLux and AstraZeneca, covering reimbursement strategy, payer engagement and HTA submissions. He began his career as a business analyst at IM Associates (now part of IQVIA). He holds an MSc in Pharmaceutical Sciences (Drug Development) from KU Leuven and a Master in Global Management from Antwerp Management School.
